Related Experiment Video

Updated: Aug 8, 2026

A Model of Cardiac Remodeling Through Constriction of the Abdominal Aorta in Rats
07:31

A Model of Cardiac Remodeling Through Constriction of the Abdominal Aorta in Rats

Published on: December 2, 2016

Apoptosis in hypertensive heart disease: a clinical approach

Arantxa González1, Susana Ravassa, Begoña López

  • 1Division of Cardiovascular Sciences, Centre for Applied Medical Research, School of Medicine, University of Navarra, Pamplona, Spain.

Current Opinion in Cardiology
|June 7, 2006
PubMed

Insights

Cardiomyocyte apoptosis, a programmed cell death, contributes to heart failure in hypertensive patients. This review explores evidence and strategies for detecting and preventing this cell death mechanism.

Area of Science:

  • Cardiovascular Medicine
  • Cell Biology
  • Pathophysiology

Background:

  • Classical view posits necrosis as the primary cardiomyocyte death mechanism in cardiac diseases.
  • Emerging evidence indicates cardiomyocyte apoptosis occurs in various conditions, including hypertensive heart disease.
  • Apoptosis may significantly contribute to cardiomyocyte loss and functional decline in hypertension.

Purpose of the Study:

  • To review recent evidence on the role of cardiomyocyte apoptosis in hypertensive heart failure.
  • To discuss strategies for detecting and preventing cardiomyocyte apoptosis.

Main Methods:

  • Literature review of studies investigating cardiomyocyte death in cardiovascular disease.
  • Analysis of experimental and clinical data on apoptosis in hypertension-related heart conditions.

Main Results:

  • Growing evidence supports cardiomyocyte apoptosis as a key factor in heart failure development in hypertensive individuals.
  • Apoptosis contributes to the loss of functional cardiomyocytes, exacerbating cardiac dysfunction.

Conclusions:

  • Cardiomyocyte apoptosis is a significant contributor to heart failure in hypertensive patients.
  • Developing methods to detect and inhibit cardiomyocyte apoptosis may offer therapeutic benefits.
  • Further research is needed to fully elucidate the mechanisms and therapeutic targets.
Abstract

More Related Videos

The Antihypertensive Effects and Mechanisms of Huotan Jiedu Tongluo Decoction in Rats with H-Type Hypertension05:57

The Antihypertensive Effects and Mechanisms of Huotan Jiedu Tongluo Decoction in Rats with H-Type Hypertension

Published on: May 17, 2024

Related Concept Videos

Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
Apoptosis01:30

Apoptosis

Apoptosis is a combination of two Greek words, 'apo' and 'ptosis,' meaning separation and falling off, respectively. Hippocrates used this word to describe gangrene, which was caused due to bandaging of fractured bones. Apoptosis was distinguished from necrosis in 1970 when John Kerr reported observations of morphological changes occurring during apoptosis. During one experiment, he observed that the disruption of blood supply to the liver tissue resulted in a size reduction of the tissue.
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...